Lab Will Support MammaPLUS Launch Set for Fall 2009

MOUNTAIN VIEW, Calif.–Perlegen Sciences, which develops genetic tests that correlate genetic variation to disease risk and drug response, announced today that it has opened the Perlegen Clinical Laboratory Services facility at its Mountain View location, following a successful inspection for CLIA (Clinical Laboratory Improvement Amendments) licensure by the California Department of Public Health’s Laboratory Field Services.

“With the opening of our CLIA lab, Perlegen can now offer information from specialized genetic tests to physicians and patients who can benefit from this additional knowledge,” said Bryan Walser, MD, CEO of Perlegen. “The efficient design, development and implementation of a lab capable of processing high-complexity genetic tests is also a significant advance in our efforts to commercialize Perlegen’s key genetic tests, starting with our planned launch of the MammaPLUS™ breast cancer risk stratifier test later this fall.”

MammaPLUS is a novel genetic test panel that will examine individual patients’ blood samples to detect the absence or presence of validated and replicated common genetic variations (SNPs) associated with an increased risk for non-familial breast cancer. MammaPLUS is designed to help physicians assess aggregate breast cancer risk from these genetic markers, plus factors from a standard clinical assessment based on a patient’s family and personal history, thus giving a clearer picture of an individual woman’s risk of developing breast cancer. MammaPLUS may be especially useful for women at intermediate risk of developing breast cancer, including those who have undergone breast biopsies, as the test will provide information that can help physicians recommend alternative courses of action, such as more vigilant, targeted surveillance or preventive therapy, on a patient-by-patient basis.

About Perlegen

Perlegen’s mission is to discover and commercialize genetic variations that can make a difference to patients and physicians. The company’s expertise is in understanding human genetic variation within and across diverse patient populations and in conducting studies aimed at identifying those variations that are predictive of drug response, including both toxicity and efficacy. For more information about the company and its technologies, visit Perlegen’s website at www.perlegen.com.

MammaPLUS is a trademark of Perlegen Sciences, Inc.